MDxHealth suspended its full-year 2026 revenue guidance of $110–115 million after reporting preliminary third-quarter revenue of approximately $22.7 million, matching the prior-year period.

The company attributed the shortfall to unexpected sales force turnover following the discontinuation of its Resolve mdx product, which disrupted execution despite disciplined forecasting processes. While liquid-based test volumes rose significantly, a decline in tissue-based tests offset the gains, resulting in flat overall revenue.

Preliminary Financial Performance

The company reported preliminary unaudited revenue from continuing operations for the quarter ended September 30, 2026. The table below details the key operational metrics compared to the third quarter of 2025 (re-presented to exclude discontinued operations).

Note: Prior-year liquid-based volume includes Select mdx and Exo mdx from the September 2025 acquisition.

Management Commentary and Corrective Actions

Michael K. McGarrity, CEO of MDxHealth, stated that third-quarter revenue fell short of expectations. The primary driver was aggressive targeting of the sales force by recruiters, catalyzed by the discontinuation of Resolve mdx. This led to an interruption in progress reported in the second quarter.

The management emphasized that these factors do not represent a change in customer reputation or underlying clinical demand. The company is focused on fortifying impacted territories and expects to return to growth within its end markets. Additional details on corrective actions will be provided during the full earnings call scheduled for November 12.

What the Numbers Show

A divergence exists between the two primary test categories. While liquid-based test volume surged to 11,792 from 4,600 in the prior year, this was insufficient to counteract the 11% decline in tissue-based test volume (11,232 tests). The result was flat total revenue, indicating that the mix shift toward liquid-based tests did not yield immediate top-line expansion relative to the loss in tissue-based volume. Additionally, cash reserves stood at $31.7 million as of September 30, 2026.

Lake Street analyst Thomas Flaten maintains a Buy rating on MDxHealth (NASDAQ: MDXH), but has lowered the price target from $5 to $3. The adjustment reflects a recalibration of the stock’s valuation ceiling while preserving the firm’s positive long-term outlook on the biotechnology company.

Analyst Action Details

The revision represents a significant contraction in the upside potential identified by the broker. While the Buy rating signals continued confidence in the company’s fundamental trajectory, the reduced target price suggests tighter near-term valuation parameters.

What the Numbers Show

The divergence between the maintained Buy rating and the sharply lowered price target indicates that Lake Street views the current market price as still undervalued relative to intrinsic worth, but acknowledges a lower ceiling for near-term appreciation. The reduction from $5 to $3 implies a reassessment of risk or growth assumptions, even as the core investment thesis remains intact.